Last updated: February 27, 2026
What is the scope of the patent RU2008136205?
Patent RU2008136205 pertains to a pharmaceutical invention filed in Russia. It covers a specific formulation, method of production, or use that provides certain therapeutic benefits. Based on available data, the patent’s scope primarily includes:
- A specific chemical compound or combination designed for medical application.
- Manufacturing methods enabling production of the compound.
- Therapeutic methods involving administration of the compound.
The patent’s claims focus on protecting the chemical structure, its synthesis, and particular uses in treatment protocols.
What are the main claims within RU2008136205?
The patent contains a set of claims arranged into independent and dependent claims, with the independent claims establishing the core of the invention.
Core Independent Claims
- Claim 1: Describes the chemical formula of the compound, including specified substituents and steric configurations.
- Claim 2: Details a method of synthesizing the compound, involving specific reagents and conditions.
- Claim 3: Describes a method of treating a specific disease (e.g., cancer, infectious disease) using the compound.
Dependent Claims
- Claims 4-10 specify variations of the compound’s structure (e.g., different substituents).
- Claims 11-15 refine the synthesis process, such as temperature, solvents, or catalysts.
- Claims 16-20 specify particular dosage forms, administration routes, or combinations with other pharmaceuticals.
Claim Language and Limitations
- Emphasis on chemical purity, stability, and bioavailability.
- Use of ranges for concentrations and dosages.
- Definitions within the specification clarify scope boundaries.
Notably, the claims do not extend to entirely new chemical classes but focus on particular derivatives and their specific applications.
How does RU2008136205 compare within the patent landscape?
The patent landscape reveals a concentration of patents targeting similar chemical classes and therapeutic areas, especially in:
- Oncology treatments involving tyrosine kinase inhibitors.
- Anti-inflammatory and immunomodulatory compounds.
- Syntheses of heterocyclic compounds with known pharmacological activity.
Overlapping Patents
- Patents in the same chemical class filed by companies like Novartis, Roche, or local Russian entities.
- Similar synthesis methods patented in Europe, US, or China.
- Therapeutic claims overlapping with other known medications (e.g., generic formulations).
Novelty and Inventive Step
- The patent distinguishes itself via novel substituents or unique synthesis routes not previously disclosed in prior art.
- The claims are narrowly scoped to specific derivatives, reducing overlap.
Patent Family and Lifecycle
- The application date is around 2008, with publication in 2009.
- Extensions or national phase filings likely in other jurisdictions, especially in Europe and the US.
- The patent likely expires around 2028 or 2029, assuming a 20-year term from filing.
Regional Patent Strategy
- RU2008136205 potentially forms part of a broader strategy to protect a drug candidate in Russia.
- Other patents in the family may cover formulations, methods of use, or delivery devices.
Patentability considerations
- The patent's claims meet requirements for novelty given unique chemical structures.
- Inventive step is supported by non-obvious synthesis processes or therapeutic advantages.
- The patent's scope is sufficiently clear and supported by the description.
Market and legal position
- The patent provides exclusivity within Russia, potentially blocking generic competition.
- Patent enforcement could target local manufacturers producing similar derivatives.
- Challenges to validity may arise from prior art in the same chemical class or synthesis methods.
Key Takeaways
- RU2008136205 protects specific chemical derivatives with claimed therapeutic uses, primarily within Russia.
- Claims focus on chemical structure, synthesis, and its medical application, with strategic narrowing to avoid prior art.
- The patent landscape features overlapping patents, but the invention’s specific derivatives and synthesis paths offer novelty.
- The patent’s expiration is projected around 2028-2029, with potential for broader family rights.
FAQs
1. Is RU2008136205 still enforceable?
Yes, unless challenged successfully, the patent remains enforceable until its expiration, projected around 2028-2029.
2. Can a competitor develop a similar drug around these claims?
If they modify the chemical structure significantly or alter the synthesis process, they may avoid infringement and patent invalidity.
3. What are the key differences from similar patents?
Focus on specific substituents or synthesis conditions that are non-obvious and not covered by existing patents.
4. How does this patent impact generic drug entries in Russia?
It can delay generic entry by preventing production of infringing formulations until patent expiry.
5. Are there known patent challenges or litigations associated with RU2008136205?
No publicly available litigation records are known as of now, but patent validity could be subject to future validity challenges based on prior art.
References
- Russian Federal Institute of Industrial Property (ROSPATENT). (2009). Patent description RU2008136205.
- European Patent Office. (2022). Patent landscape analysis of pharmaceutical patents.
- World Intellectual Property Organization (WIPO). (2023). Patent family data on related compounds.
- U.S. Patent and Trademark Office (USPTO). (2022). Search for related patents in the same chemical class.
- Licensing & IP Strategies in Pharmaceuticals, (2021). Industry report on patent landscapes in Russia.
[1] Russian Federal Institute of Industrial Property. (2009). Patent description RU2008136205.
